This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alexion Pharmaceuticals Inc (ALXN)

NASDAQ: Health Care

Company Income Statement
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Sales 2.23B 1.55B 1.13B 783.43M
Cost of Sales 111.40M 146.04M 102.74M 75.93M
Gross Operating Profit 2.12B 1.41B 1.03B 707.50M
Selling, General, and Administrative Expenses 630.21M 489.72M 384.68M 308.18M
Research & Development 513.78M 317.09M 222.73M 137.42M
Operating Income before D & A (EBITDA) 978.34M 598.49M 423.96M 261.90M
Depreciation & Amortization 62.46M 31.93M 23.89M 17.59M
Interest Income 8.37M 3.35M 1.84M 1.91M
Other Income - Net -1.99M -975.00K 52.17M -2.28M
Special Income / Charges -11.51M -33.52M -26.30M 0.00
Total Income Before Interest Expenses (EBIT) 875.09M 530.38M 404.97M 230.46M
Interest Expense 2.98M 4.11M 7.40M 788.00K
Pre-Tax Income 872.11M 526.27M 397.57M 229.67M
Income Taxes 215.20M 273.37M 142.74M 54.35M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations 656.91M 252.90M 254.82M 175.32M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 656.91M 252.90M 254.82M 175.32M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 656.91M 252.90M 254.82M 175.32M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
704.09M 291.44M 303.93M 188.80M
Preferred Dividends
Net Income Available To Common 656.91M 252.90M 254.82M 175.32M
Basic EPS from Continuing Ops. 3.32 1.29 1.34 0.96
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 3.32 1.29 1.34 0.96
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 3.32 1.29 1.34 0.96
Basic Normalized Net Income/Share 3.55 1.49 1.60 1.03
EPS fr Continuing Ops. 3.26 1.27 1.28 0.91
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 3.26 1.27 1.28 0.91
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total 3.26 1.27 1.28 0.91
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
3.49 1.46 1.53 0.98
Dividends Paid per Share 0.00 0.00 0.00 0.00
ALXN News

ALXN Alexion Pharmaceuticals Inc

Chart of ALXN

Analysts Ratings for ALXN

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 14 14 14 14
Moderate Buy 0 0 1 1
Hold 3 3 2 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET ALXN ANALYST REPORT

Brokerage Partners

ALXN Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs